Dee Parson Grange Email & Phone Number

-Directs and develops global brand strategies and lifecycle management to achieve Company’s strategic objectives for assigned inline and pipeline products/franchises (+$2B Franchise)-Responsible for new indication market development and global launch of new immunology product serving immunology, hematology / oncology, Pulmonology, Rheumatology, and Neurology patients-Expands indications for existing products and enlarges portfolio with new products -Directs, plans and formulates global strategies for assigned brands/franchises, including creating and presenting global strategic plans, while seeking input from stakeholders -Provides commercial development activities (development of business cases, commercial forecasts, pricing & reimbursement strategies, target product profile development, active participation on project teams) and market development activities (marketing communications strategy, publications plan, KOL development) for new and existing pipeline projects-Identifies and directs new business to grow therapeutic areas of its responsibility, identification of synergies with other products and divisions and development of disease management strategies-Works closely with R&D and clinical to improve portfolio and accomplish customers needs-Directs market analysis and research, global operative activities, and consistently engages with key internal and external stakeholders to ensure business priorities are achieved-Strong understanding of global marketing issues, priorities and competitive threats to develop effective marketing and product/franchise strategies, including disease management-Directs analyses and market research to better understand global and key regional trends and issues relevant to the brand and global strategic and operative activities-Assesses opportunities and informs internal stakeholders of any significant new development or opportunity-Multi-channel marketing

Serving Us And Global Markets

-Global Product and Portfolio Strategy-New Product Planning and Commercialization-Global Marketing-Product Innovation-Strategic Planning / Forecasting-Brand Development-Product and Portfolio Management-US HCP, Patient and Payer Marketing-Opportunity Assessment-Partnering (In-licensing/Out-licensing) and Alliance Management-Patient AdvocacyRecent contract:Interim Head of Commercial and Medical Affairs responsible to prepare for launch in the United States for a rare oncology product that required establishing and implementing both a business and commercial plan for an Ex-US company entering US without commercial expertise or infrastructure. US business and commercial plans were developed from white space through to Board approval, supported by a 10 year validated budget. In parallel, rolled-up sleeves to develop and implement pre-launch commercial programs that included:-Brand Development -Brand Name Approval-Multi-channel marketing-Expanded Access Program-Patient Advocacy Program-Market Segment Development-Medical Affairs Porgram-Public Relations and Digital Program-Sales Force and Managed Markets Development-Coordinated and aligned with corporate headquarters in Asia and EU and Japanese partnersChaired Therapeutic Area Partnership Meeting in Boston, November 2015

-Partnering of novel base technology platform and pipeline products-Alliance management -New product planning -Product management-Corporate Communications-Cross-Functional Project Management-Business case development / Forecasting-Opportunity assessments-KOL management-Scientific/medical publication strategy and implementation-Meeting and corporate presentation strategy implementation-Press release strategy and implementation-Digital communications-Website implementation-Market research-Vendor management-Budget management-Disease state focus: Hepatitis C, Hemodialysis Graft, Deep Vein Thrombosis, Acute PAO, Oncology-Novel technology: Genetically altered plants producing therapeutic proteins

Globally launched re-branded 60-year-old fluid-management product leveraging unique positioning and creative non-personal selling peer-to-peer approach with world class cardiovascular surgery medical faculty. In parallel, developed separate commercial business-to-business market for same product line to be used as excipient within other products, leveraging a regulatory package approved in over 30 countries.Increased demand revitalized markets, lowered inventory levels and increased pricing.-Product strategy-Product launch-Product management-Opportunity assessment-Promotional material development-Medical, legal and regulatory approvals-Program implementation-Analytical thinking / creative problem solving-Cross-functional team leadership-Agency and vendor management-Budget management-Forecasting / Inventory management-Pricing / reimbursement programs -Globally managed Regional/local affiliates, distribution partners, RFP/Tender opportunities-Excipient B2B business model required different product, contract and distribution models

Corporate Division Experience: Biotech, Pharmaceutical, AllergyDisease state focus: Immunology, Neurology Autoimmune, Bone Marrow Transplantation, Respiratory including Genetic emphysema, Hemophilia, Thrombosis, Antibiotics, Immuno-therapyProduct Experience: Rare disease specialty products: Immunoglobulins, Hyperimmunes, Alpha-1 Proteinase Inhibitor, Antithrombin, FVIII, FIX, Human Serum AlbuminBlockbuster: Cipro Direct sales to Physician: Allergy extracts for office based immuno-therapy Commercial Responsibilities included:-New product planning -Strategic marketing and Life-cycle management-Forecasting and Business Case Development-Product and Portfolio management-Brand Development-Sales Operational Plans-Sales Training including technical lectures-Direct to physician sales-Team development and mentoringBusiness Operations Responsibilities included:-Business Strategy and budget development-P&L Accountability-Supply Chain management: Direct reports included Forecasting and Customer Service-Project management -Cross-functional leadership-Supported due diligence process and post-M&A business restructuring-Business re-engineering core team

Mba, Gemba

Activities and Societies: Duke Global Executive MBA Class of 2005 --Class Liaison as voted by Peers --Initiated China School Project.

Bs, Biology, Chemistry, Communications

Activities and Societies: Competed at national level in the categories of persuasive, informative, impromptu, and extemporaneous speaking.